Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Aimmune Therapeutics, Inc is a biotechnology business based in the US. Aimmune Therapeutics shares (AIMT) are listed on the NASDAQ and all prices are listed in US Dollars. Aimmune Therapeutics employs 339 staff and has a trailing 12-month revenue of around USD$575,000.
|52-week range||USD$10.09 - USD$37|
|50-day moving average||USD$34.3242|
|200-day moving average||USD$20.2628|
|Wall St. target price||USD$31.28|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.726|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Aimmune Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Aimmune Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Aimmune Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.16. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Aimmune Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Gross profit TTM||USD$0|
|Return on assets TTM||-53.24%|
|Return on equity TTM||-149.17%|
|Market capitalisation||USD$2.3 billion|
TTM: trailing 12 months
There are currently 4.2 million Aimmune Therapeutics shares held short by investors – that's known as Aimmune Therapeutics's "short interest". This figure is 38% down from 6.7 million last month.
There are a few different ways that this level of interest in shorting Aimmune Therapeutics shares can be evaluated.
Aimmune Therapeutics's "short interest ratio" (SIR) is the quantity of Aimmune Therapeutics shares currently shorted divided by the average quantity of Aimmune Therapeutics shares traded daily (recently around 4.2 million). Aimmune Therapeutics's SIR currently stands at 0.99. In other words for every 100,000 Aimmune Therapeutics shares traded daily on the market, roughly 990 shares are currently held short.
However Aimmune Therapeutics's short interest can also be evaluated against the total number of Aimmune Therapeutics shares, or, against the total number of tradable Aimmune Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aimmune Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Aimmune Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0903% of the tradable shares (for every 100,000 tradable Aimmune Therapeutics shares, roughly 90 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aimmune Therapeutics.
Find out more about how you can short Aimmune Therapeutics stock.
We're not expecting Aimmune Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Aimmune Therapeutics's shares have ranged in value from as little as $10.09 up to $37. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aimmune Therapeutics's is 1.7408. This would suggest that Aimmune Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California. As of October 9, 2020, Aimmune Therapeutics, Inc. operates as a subsidiary of Société des Produits Nestlé S.A.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.